Jump to content

Using T Cells to Tackle Drug Resistance in EGFR+ Lung Cancer


Recommended Posts

"Our goal is to use T cell engineering to stop DTPCs from growing and ultimately prevent the development of drug resistance in patients who are living with EGFR-positive lung cancer. This would improve not only the duration of their lives, but also the quality."

Read our interview with Dr. Alexandre Reuben as he discusses using T cells to tackle drug resistance in EGFR+ lung cancer.


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.